<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>HOUSE OF COMMONS SCIENCE AND TECHNOLOGY COMMITTEE INQUIRY INTO ANTIMICROBIAL RESISTANCE</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by the Department of Health (AMR0043)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Introduction</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0.1pt 0pt 0pt 13.25pt; padding-left:10pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Work to address </span><span style="font-family:'Times New Roman'; font-size:11pt">resistance of a microorganism to an antimicrobial (mainly, but not exclusively, antibacterial) medicine</span><span style="font-family:'Times New Roman'; font-size:11pt">, commonly described as antimicrobial resistance (AMR), has been underway for many years, by a number of bodies at a national and international level. </span><span style="font-family:'Times New Roman'; font-size:11pt">Despite these efforts AMR has continued to develop and spread</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt">, and is a global problem. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 12pt 13.25pt; padding-left:10pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK published its first AMR strategy and action plan in 2000</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt">.  The World Health Organisation (WHO) held a series of meetings that culminated in publication of its global strategy in 2001</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Times New Roman'; font-size:11pt">. The European Commission published its EU AMR Strategic Action Plan in 2011, and these documents informed the development of the recently published UK AMR Strategy. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0.1pt 0pt 0pt 13.25pt; padding-left:10pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">As the Chief Medical Officer’s annual report in March 2013</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:'Times New Roman'; font-size:11pt"> explained, infection control needs to extend its focus beyond meticillin-resistant</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> Staphylococcus aureus</span><span style="font-family:'Times New Roman'; font-size:11pt"> (MRSA) and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile </span><span style="font-family:'Times New Roman'; font-size:11pt">to include broader issues including the increase in multi-resistant organisms for which there are relatively few effective therapies to treat infections, and in particular the spread of Gram-negative bacteria</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Times New Roman'; font-size:11pt"> resistant to a range of antibiotics. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:10pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In response to the Chief Medical Officer’s call to action, in September 2013 the Government published a new UK Five year Antimicrobial Resistance Strategy</span><a name="_ftnref6"></a><a href="#_ftn6">[6]</a><span style="font-family:'Times New Roman'; font-size:11pt">, which seeks to build on earlier work in a co-ordinated manner, to tackle the challenges which have hitherto hindered progress. </span><span style="font-family:'Times New Roman'; font-size:11pt">Key actions being taken will improve how we prevent and manage infections in people and animals, improve education and training on the prescribing of antibiotics, collect better data on the resistance of microorganisms so we can track them more effectively, support further research into antimicrobial resistance, and explore ways to encourage the development of new antibiotics.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">How has antimicrobial resistance developed in the past decade? </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:10pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The European Centre for Disease Prevention and Control’s (ECDC) European Antimicrobial resistance Surveillance network (EARS-Net) system collects data to assess resistance trends across the EU for </span><span style="font-family:'Times New Roman'; font-size:11pt">seven bacterial pathogens</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">commonly causing infections in humans. </span><span style="font-family:'Times New Roman'; font-size:11pt">Rates of resistance vary across Europe. </span></li></ol><p style="background-color:#ffffff; margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:10pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In the case of meticillin-resistant </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus aureus</span><span style="font-family:'Times New Roman'; font-size:11pt"> (MRSA), resistance patterns ranged from 1% to 40% during the period 1993 to 2012, with the UK being one of high prevalence countries for the majority of this period.  However, by 2011, MRSA cases in the UK had fallen to 13.6% and the UK now is amongst those with the lowest rates of MRSA in Europe.</span></li></ol><p style="background-color:#ffffff; margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:10pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">However, ECDC has reported </span><span style="font-family:'Times New Roman'; font-size:11pt">a significant rise in infections across the EU caused by Gram-negative bacteria, which are becoming increasingly resistant. Such resistance has diminished the number of antibiotics that remain effective against these organisms. </span><span style="font-family:'Times New Roman'; font-size:11pt"> Resistant Gram-negative Enterobacteriaceae (including </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Escherichia coli</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Klebsiella</span><span style="font-family:'Times New Roman'; font-size:11pt"> and related species of bacteria) are </span><span style="font-family:'Times New Roman'; font-size:11pt">becoming a pressing problem in the UK.  Levels of resistance specifically to carbapenem antibiotics, which are the last-line drugs used to treat infections caused by Gram-negative bacteria, are low but increasing.</span></li></ol><p style="background-color:#ffffff; margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:10pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In the UK, resistance in </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> to the very widely used broad spectrum antibiotic ciprofloxacin increased year-on-year from approximately 5% in 2000 to nearly 25% in 2006-2007, while resistance to third-generation cephalosporins (important antibiotics used in hospital care) increased from 2% to 12% over the same period. Although rates of resistance to both drugs have showed a slight decline since 2007, rates have now plateaued at about 20% and 10% respectively. There is also concern about the increase in resistance to alternative newer drugs to treat </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections, such as piperacillin, tazobactam and meropenem. Although resistance to meropenem is still relatively uncommon in bloodstream isolates of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt">, there appears to be increasing evidence of widespread transmission via the gut, which may lead to resistance in invasive infections. This is a major concern as meropenem is a “drug of last resort”.  </span></li></ol><p style="background-color:#ffffff; margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:10pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Another area of concern is m</span><span style="font-family:'Times New Roman'; font-size:11pt">ultidrug-resistant tuberculosis (MDR-TB).  A report</span><a name="_ftnref7"></a><a href="#_ftn7">[7]</a><span style="font-family:'Times New Roman'; font-size:11pt"> from Public Health England (PHE) shows that in the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">the proportion of TB cases with resistance to any first line drug (7.4 %) was slightly lower in 2012 than in 2011 and the proportion of multi-drug resistant (MDR) TB cases  is 1.6 %.  The majority of cases with MDR TB (89%) were born outside the UK. </span><span style="font-family:'Times New Roman'; font-size:11pt">Despite the </span><span style="font-family:'Times New Roman'; font-size:11pt">considerable efforts to improve TB prevention, treatment and control, the incidence of TB in the UK remains high compared to most other Western European countries, with 8,751 cases reported in 2012, an incidence of 13.9 per 100,000 population. In terms of MDR TB, the total number of cases in the UK between 1995 and 2011 is 24.  Six of these cases were reported in 2011, the highest number in any single year since 1995. </span></li></ol><p style="background-color:#ffffff; margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Rates of gonorrhoea have risen by 25% cent in the last year. In the last 50 years, gonorrhoea has evolved to beat four different types of antibiotics, each stronger than the last, and an increasing number of global cases involve antibiotic resistant strains of Neisseria gonorrhoea</span><a name="_ftnref8"></a><a href="#_ftn8">[8]</a><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="background-color:#ffffff; margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We are also seeing an increase in the number of MDR bacteria of all types across the globe, and with the increase in travel movements we are seeing transmission between countries at an increasing rate. The UK is also witnessing an increase in the number and type of resistant infections being imported from other countries. Patients repatriated after hospitalisation abroad are potential carriers of MDR microorganisms, which can be introduced into hospitals in their home countries unless good admissions screening and isolation precautions are taken.   </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Given the resistance trends, our primary and urgent need is for new antibiotics to treat Gram-negative infections (such as </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">.coli, klebsiella </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> Pseudomonas)</span><span style="font-family:'Times New Roman'; font-size:11pt">. There is a need for both broad spectrum and narrow spectrum (i.e. pathogen specific) agents to manage these infections as we have few effective treatments for these pathogens.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> New treatments are needed within the next 3-5 years if we are to be in a position to contain the spread of resistant infections. Linked to this must be a renewed emphasis on strong infection prevention and control processes to limit onward spread. New antibiotics for Gram-positive infections (such as </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus aureus</span><span style="font-family:'Times New Roman'; font-size:11pt">) are also needed, but this is a less pressing issue, as we have a wider range of effective and new treatments for these bacteria. The supply of effective treatments for tuberculosis also needs to be maintained. In addition we need to consider the role of alternative or novel treatment approaches including extending the use of vaccines to prevent infections.</span></li></ol><p style="background-color:#ffffff; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The role of specific healthcare settings is also important in terms of changing demographics. The population of this country is ageing. Currently, in England there are over 9 million people aged 65 or more and they form almost 17% of the total population (roughly 1 in 6).</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">Most of our elders live in the community (homes and care homes), and in addition may be admitted to hospital for </span><span style="font-family:'Times New Roman'; font-size:11pt">acute treatment.   This carries the risk of transferring AMR between hospital and the community. This population group has increased in size by more than 15% since 2001, compared with a 6.5% increase in those aged under 65. </span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">The population of people aged 65 or more is projected to rise by another 4.5 million in the next 20 years and will then form 22% of the total population, compared with the 17% now. The increases in this older age group are likely to result in a matching increase in the numbers of the elderly in some form of residential care – recently estimated to be around 330,000, and projected to rise by at least 50% in the next 20 years.</span><a name="_ftnref9"></a><a href="#_ftn9">[9]</a><span style="font-family:'Times New Roman'; font-size:11pt"> These older people currently account for over 69% of the combined cases of the 4 reported infections,</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli, MSSA and </span><span style="font-family:'Times New Roman'; font-size:11pt">MRSA, which demonstrates the much higher vulnerability to infection of the elderly.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What are the gaps in our knowledge about antimicrobial resistance? </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 2pt 0pt 23.25pt; text-align:justify; text-indent:-23.25pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The Department of Health and PHE are working together to assess the existing evidence base and improve our knowledge and understanding of AMR. </span></li></ol><p style="margin:0pt 2pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 2pt 0pt 23.25pt; text-align:justify; text-indent:-23.25pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Better surveillance data are needed to improve our understanding of the</span><span style="font-family:'Times New Roman'; font-size:11pt"> epidemiology of infections, antibiotic use, monitor resistance trends in key organisms, and assess the impact of rational prescribing programmes for current and new antibacterial agents in humans and animals. </span></li></ol><p style="margin:0pt 2pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The use of antimicrobials is a known driver for resistance. The potential role of alternative approaches, including the use of vaccines, could be exploited further and is an active area of research. If successful this would reduce our reliance on antibiotics considerably.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">While data for total antibiotic usage in the community are available, data on antibiotic usage in hospitals have, until recently, not been available more generally.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Inappropriate antimicrobial stewardship has also contributed to the development of AMR.</span><span style="font-family:'Times New Roman'; font-size:11pt"> To this end, in January 2012, the National Institute for Health and Care Excellence (NICE) published a Quality Improvement Guide</span><a name="_ftnref10"></a><a href="#_ftn10">[10]</a><span style="font-family:'Times New Roman'; font-size:11pt">, on the prevention and control of healthcare associated infections, and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Identifying and managing tuberculosis among hard-to reach groups,</span><span style="font-family:'Times New Roman'; font-size:11pt"> which has particular relevance to tackling drug resistant TB</span><a name="_ftnref11"></a><a href="#_ftn11">[11]</a><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To improve stewardship practices the NICE are progressing work (agreed with the Department of Health and Public Health England), to produce Good Practice Guidance on antimicrobial stewardship, a full Clinical Guideline on reducing mortality and morbidity from healthcare associated infections, and a Public Health Guideline on advice to the public about AMR.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt 2pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 2pt 0pt 23.25pt; text-align:justify; text-indent:-23.25pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Although surveillance programmes have improved dramatically, information on the impact of antibiotic use on patient outcome and development of resistance is limited. Antibiotic </span><span style="font-family:'Times New Roman'; font-size:11pt">prescription data for humans are currently only collected centrally for primary care. This needs to be extended to all areas of healthcare, especially secondary care. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 2pt 0pt 23.25pt; text-align:justify; text-indent:-23.25pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary antibiotic sales data are collated and published annually, and used as proxy measures of the amount of antibiotic used in animals in the UK. However there are limitations with this approach, particularly in determining the antibiotic quantities used in different animal species. At present, there is no central collection of prescription data for veterinary medicines in the UK. Options for collection and analysis of such information are being explored.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="22" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 1.9pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We also need to be able to assess trends in resistance in primary and secondary healthcare settings, and in particular, susceptibility of key bacteria to the WHO defined critically important antimicrobials (CIA)</span><a name="_ftnref12"></a><a href="#_ftn12">[12]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:11pt">used in human medicine.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> This would enable us to control resistance in a way that avoids undesirable and unintended consequences for patient safety. Enhanced surveillance arrangements are being put in place to better monitor trends and changes in resistance in a range of bacteria commonly associated with infections for which there are very limited treatment options across the UK. </span></li></ol><p style="margin:0pt 1.9pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="23" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 1.9pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK AMR Strategy identifies the priority areas for monitoring resistance in the UK. PHE has recently set up a new group, the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR)</span><a name="_ftnref13"></a><a href="#_ftn13">[13]</a><span style="font-family:'Times New Roman'; font-size:11pt"> to focus its monitoring on resistance trends around the following drug/bug combinations</span><a name="_ftnref14"></a><a href="#_ftn14">[14]</a><span style="font-family:'Times New Roman'; font-size:11pt"> in the first instance:</span></li></ol><p style="margin:0pt 0pt 10pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Multi Drug Resistant Bacteria</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Metric</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Klebsiella - carbapenem</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">% non-susceptible to imipenem &amp;/or meropenem</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> - cephalosporin</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">% non-susceptible to cefotaxime &amp;/or</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">ceftazidime</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> - fluoroquinolone</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">% non-susceptible to ciprofloxacin</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Pseudomonas - carbapenem</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">% non-susceptible to imipenem &amp;/or meropenem</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">N. gonorrhoeae</span><span style="font-family:'Times New Roman'; font-size:11pt"> - ceftriaxone</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">% non-susceptible</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Klebsiella - cephalosporin</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">% non-susceptible to cefotaxime &amp;/or ceftazidime</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Pseudomonas - cephalosporin</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">% non-susceptible to ceftazidime</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> - gentamicin</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">% non-susceptible</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">S. pneumoniae</span><span style="font-family:'Times New Roman'; font-size:11pt"> - penicillin</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:231.05pt"><p style="margin:0pt 1.9pt 10pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">% non-susceptible</span></p></td></tr></table><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="24" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The above antibiotics have been selected because they are routinely used in healthcare setting to manage hard to treat infections. Currently, there are no new treatments to replace these and we have to rely on good antibiotic stewardship to conserve their efficacy. The success of this approach depends on everyone in the healthcare system using the right drug, in the right way for the right duration. We know this is not routinely happening, hence our focus on education to improve clinical practice, training and awareness raising activities such as European Antibiotic Awareness Day (EAAD), which is aimed at both the public and healthcare professionals.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="25" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To gain a better understanding of the volume and type of antimicrobials in use, PHE is bringing together via the ESPAUR programme the elements of antimicrobial utilization and resistance surveillance in primary and secondary care settings.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="26" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 1.9pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In addition, there is a need to improve the surveillance data on the animal health side, if we are to firstly, better understand the links between resistance in animals and in humans, and secondly, </span><span style="font-family:'Times New Roman'; font-size:11pt">to minimise the risk of resistance developing in animals to the WHO-defined critically important antimicrobials in human medicine.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="27" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The transmission (or carriage) of resistant infections within primary healthcare and the wider community is less well understood than hospitals.  Patients who are admitted to hospital with an infection, or who develop an infection while in hospital, are subject to microbiological investigations to diagnose the cause of that infection and the appropriate treatment administered. This also includes assessing antibiotic susceptibility of the causative bacteria and helps us understand antibiotic resistance within the hospital setting. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="28" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">By contrast, patients treated in the community by GPs are usually not investigated microbiologically. Instead, the GP assesses the likely cause of infection on clinical grounds and prescribes an antibiotic empirically. Information on rates of AMR among bacteria causing common infections in the community, such as urinary tract, skin or respiratory infections, are not routinely available. As 70-80% of antibiotics prescribed to patients are prescribed in the community, the lack of data on rates of resistance is a significant knowledge gap. Where GPs send specimens to the microbiology laboratory for investigation this is usually for patients who have failed treatment, or have complicated infections.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="29" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In both settings, antibiotics may be prescribed without knowing the precise micro-organism causing the infection and broad spectrum agents are often used to ensure effective treatment. Rapid point of care diagnostics would help prescribers tailor treatment to individuals by allowing the use of narrow spectrum antibiotics.  Routine use of rapid point of care diagnostic tests to distinguish bacterial and viral infections would be especially useful for primary care to prevent the inappropriate use of antibiotics for upper respiratory tract infections such as sore throats, reduce the total use of antibiotics and improve the quality of prescribing more generally. Despite advances in the development of diagnostics, we are still some way off having rapid, reliable tests which are suitable for routine use in clinical settings.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="30" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Genetic information – DNA codes - can be transferred between microorganisms, and the impact of this process on the development of AMR is not well understood. The development of genome sequencing, where the whole DNA code of an organism can be read, will provide the opportunity to study in more detail the DNA code of resistant infectious microorganisms, the transfer of DNA codes between microorganisms and its potential impact on AMR, as well as the possible origins of resistant microorganisms. </span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="31" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Understanding the relative importance of resistance in humans and animals and their inter-relationship is an area where more research is needed in order to provide a rational basis for developing potential intervention strategies. Enhanced genetic sequencing of animal and human isolates would support this.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 1.9pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection?  If not, how could this be rectified?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="32" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The National Institute for Health Research (NIHR) and the Department of Health Policy Research Programme (PRP) currently fund a wide range of research on prevention, detection, diagnosis and treatment of infection. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Substantial portfolios of infection research are funded by the Health Technology Assessment programme and through Programme Grants for Applied Research. These and six other NIHR managed research programmes are participating in a themed call which covers all aspects of translational, clinical and public health research that could contribute to a reduction in the spread </span><span style="font-family:'Times New Roman'; font-size:11pt">or occurrence of AMR. The NIHR invests over £4.9 million annually over five years</span><a name="_ftnref15"></a><a href="#_ftn15">[15]</a><span style="font-family:'Times New Roman'; font-size:11pt"> in translational research in infection in its Biomedical Research Centres.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="34" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In addition, </span><span style="font-family:'Times New Roman'; font-size:11pt">on 29 May 2013,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the NIHR announced funding for four Diagnostic Evidence Co-operatives, to generate evidence of the clinical validity, clinical utility, cost-effectiveness and care pathway benefits of in vitro diagnostic medical devices that have the potential to lead to improvements in healthcare services and the quality of life of NHS patients. Two of these will focus part of their work on clinical areas relevant to infection.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="35" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The NIHR has also launched a competition to fund Health Protection Research Units. These will be partnerships between universities and Public Health England in a range of priority areas. One of these will focus on healthcare associated infections and AMR. The Units will run from April 2014 for five years. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="36" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A further £16.5 million is provided by a partnership of seven funders including the NIHR, under the umbrella of the UK Clinical Research Collaboration, the Translational Infections Research Initiative which runs from 2008 to 2015 to carry out research in microbiology and infectious diseases.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="37" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Health Innovation Challenge Fund, jointly funded by the Department of Health and the Wellcome Trust, is providing £2.8 million over three years to research the use of genomic technology to inform outbreak recognition and national surveillance, which will help enable whole genome sequencing to improve patient care, local outbreak recognition and national surveillance.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="38" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Research Councils also provide significant investment in bacteriology and antimicrobial research.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> In the financial year 2011/2012 the Medical Research Council (MRC), the Biotechnology and Biological Sciences Research Council (BBRC) and Engineering and Physical Sciences Research Council (EPSRC) invested approximately £19.6m (£6.3m BBSRC, £4.8m MRC, £8.5m EPSRC) in antimicrobial resistance research</span><a name="_ftnref16"></a><a href="#_ftn16">[16]</a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="39" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Research on AMR is also the focus of international consortia. The Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPOA) have committed €221m and €210m respectively to funding AMR consortia. This has been used for a variety of work to extend the range of commercial compounds which are active against Gram-negative resistant bacteria. These projects are supported to differing degrees by industry. In addition to projects directly addressing AMR, there are a number of IMI funded projects exploring vaccination and immunisation approaches.  </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="40" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Committee will also wish to note that the IMI Initiative “New drugs for Bad Bugs” programme has been supported by UK pharmaceutical industry</span><a name="_ftnref17"></a><a href="#_ftn17">[17]</a><span style="font-family:'Times New Roman'; font-size:11pt">. The IMI2 programme which will be launched in 2014 will make it easier for small and medium enterprises (SMEs) to contribute to this programme. Within the UK, the Technology Strategy Board, has an important role in promoting innovation amongst these enterprises in developing novel technologies on AMR. To this end, it provides grants for SMEs to finance life science solutions through its Biomedical Catalyst and Smart programmes.  It is also scoping a </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Catapult centre in Diagnostics for Stratified Medicine</span><span style="font-family:'Times New Roman'; font-size:11pt">. The centre will be a</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">focal point for those developing diagnostics leading </span><span style="font-family:'Times New Roman'; font-size:11pt">to stratified approaches to patient treatment and infectious diseases. The Catapult initiative will support businesses with expertise and infrastructure in diagnostics development and implementation. It will also allow those developing treatments to explore new ways of undertaking trials of their products supported by improved diagnostic capabilities. In addition, in 2013 the Government expanded the amount of funding available through the Small Business Research Initiative to support SMEs overcome the barriers to innovation and assisting them get new ideas to market.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="41" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Despite the investments into AMR related rapid diagnostic research, more needs to b</span><span style="font-family:'Times New Roman'; font-size:11pt">e done to improved target identification and validation, together with improved screening, to identify resistance at the earliest stages of infection.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Research is also needed to increase the range of innovative approaches to address AMR, and to widen the search for agents that will attack different parts of the bacteria. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens? </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="42" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AMR is a complex, multi-factoral issue. The UK strategy has identified seven areas for action</span><a name="_ftnref18"></a><a href="#_ftn18">[18]</a><span style="font-family:'Times New Roman'; font-size:11pt">. The success of reducing </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Clostridium difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections and MRSA bloodstream infections in England has shown it is possible to control such infections, with concerted efforts by a number of agencies in a coordinated manner. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="43" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In the case of action on MRSA, the major reduction in these infections has been achieved as a result of a combination of actions.  These include </span><span style="font-family:'Times New Roman'; font-size:11pt">the introduction of mandatory MRSA bacteraemia surveillance accompanied by objectives for MRSA, which when breached, resulted in financial consequences for the NHS Trust. The reinforcement of infection control practice like good hand hygiene, contact precautions and admission screening, and the use of decolonising agents in intensive care units (ICUs), which have high endemic rates and a complex patient population, has been an important factor in reducing ICU MRSA transmission</span><a name="_ftnref19"></a><a href="#_ftn19">[19]</a><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="44" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We have continued to focus our activities around the need to improve infection prevention and control and prevent infections in the first place, </span><span style="font-family:'Times New Roman'; font-size:11pt">conserve and steward </span><span style="font-family:'Times New Roman'; font-size:11pt">existing treatments. The Code of Practice</span><a name="_ftnref20"></a><a href="#_ftn20">[20]</a><span style="font-family:'Times New Roman'; font-size:11pt"> which was first developed in 2006 sets out 10 criteria for providers of healthcare to apply in order to demonstrate that they have adequate systems in place for the prevention and control of infection. The Department has continued to fund the development and update of evidence based guidelines for use in clinical settings (epic2: National Evidence-Based Guidelines for Preventing Healthcare-Associated Infections in NHS Hospitals in England (2007)</span><a name="_ftnref21"></a><a href="#_ftn21">[21]</a><span style="font-family:'Times New Roman'; font-size:11pt">. Equally, resources such as Start Smart then Focus</span><a name="_ftnref22"></a><a href="#_ftn22">[22]</a><span style="font-family:'Times New Roman'; font-size:11pt"> and Target provide a framework to help to reduce unnecessary use of antibiotics and promote best practice. Recognising that infections can also be a concern in care homes, a comprehensive information resource on infection prevention and control for care home managers was published in February 2013. This resource was received positively and is used widely by the care home community</span><a name="_ftnref23"></a><a href="#_ftn23">[23]</a><span style="font-family:'Times New Roman'; font-size:11pt">. Prescribing </span><span style="font-family:'Times New Roman'; font-size:11pt">competencies have also been developed by ARHAI and PHE to help facilitate optimal use of antibiotics</span><a name="_ftnref24"></a><a href="#_ftn24">[24]</a><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> They have been designed to complement the NICE National Prescribing Centre’s generic competency framework.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Regulators, education providers and professional bodies are being encouraged to use them to inform the development of standards, guidance and training. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="45" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Department of Health’s Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infections, ARHAI, together with the Health Protection Agency (now PHE) also issued guidance on multiple resistant Gram-negative bacteria in 2011</span><a name="_ftnref25"></a><a href="#_ftn25">[25]</a><span style="font-family:'Times New Roman'; font-size:11pt">. This guidance will be supplemented by a new toolkit for secondary care, which PHE expect to be in a position to publish by the end of 2013. A similar tool for the community is being user-tested. PHE has also strengthened surveillance for these organisms and encourages the NHS to submit isolates for confirmatory testing. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="46" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt"> We know that resistant bacteria are hard to control if local measures fail. Therefore vigilance is needed to control resistant pathogens in order to contain AMR at an early stage.  NHS England has an important role in ensuring changes in clinical practice. In addition, new levers and possible indicators will need to be considered. We recognise that this will be challenging as it will require changes in attitude and practice. To this end, we are working with Health Education England (HEE), which is responsible for leading improvements in the education and training of healthcare workers. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="47" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Greater transparency will be required in notifying healthcare establishments, when patients are colonised with, or infected by, carbapenemase producing bacteria and are being transferred from one establishment to another.  If applied appropriately and consistently this approach will enable the receiving establishment to take appropriate action (such as isolation). The culture needs to change to recognise that openness is essential to controlling multiply resistant bacteria.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="48" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Prescribers also need support in understanding the limitations of their local surveillance data, and cross disciplinary communication will be vital in improving standards in prescribing.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Therefore, work to develop metrics and clinical outcome measures to improve antibiotic prescribing is being undertaken by ARHAI, ESPAUR and PHE.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> This will also provide data to help improve our ability to model and forecast resistance trends, and identify priority areas for drug development.</span><span style="color:#ff0000; font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="49" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To strengthen our ability to contain the spread of AMR we will learn from the experience of other countries. In this way we will avoid the need for resource intensive, national retrospective action to reverse the spread of resistant bacteria. In Israel, for example, mandatory physical separation of carriers of the bacteria, and the establishment of a national task force were among the measures needed to bring the problem back under control</span><a name="_ftnref26"></a><a href="#_ftn26">[26]</a><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="50" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">New drugs and diagnostics offer future benefits, but until they are available, effective infection prevention and control will continue to be essential. Good</span><span style="font-family:'Times New Roman'; font-size:11pt"> primary infection prevention is crucial for reducing the need for antibiotics in the first place. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Behaviour change and AMR </span></p><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="51" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK AMR Strategy recognises that effecting behaviour change among health professionals and the public is a vital, particularly in terms of prescribing practice. A good example of efforts to achieve behaviour change internationally is EAAD. The UK uses this initiative to improve both public and professional awareness of AMR and encourage appropriate use of antibiotics. Similar initiatives are also undertaken in the USA, Canada and several European States. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="52" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Since 1999, the Department of Health has provided educational materials and other resources to help reduce unnecessary use of antibiotics and slow the development of antibiotic resistance.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Since 2008 these efforts have been focused around EAAD on 18 November each year. The outputs of these activities are evaluated and publically available. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="53" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Our evaluation of EAAD activities has confirmed that EAAD contributes to improving patient care and provides an excellent platform to raise professional and public awareness about appropriate antibiotic use which helps drive improvements in clinical prescribing practice.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> However, understanding is not universal and sustained campaigns are required to educate new generations. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="54" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Multifaceted interventions can be effective, and those that are based on cognitive theories and consider personal attitudes, subjective norms and perceived behavioural controls (confidence and other barriers) are more likely to be successful. Persuasive and restrictive interventions can be used to reduce the total use of antibiotics, and broad-spectrum antibiotics in the hospital, community and care home settings.  A recent Cochrane review</span><a name="_ftnref27"></a><a href="#_ftn27">[27]</a><span style="font-family:'Times New Roman'; font-size:11pt">,  found that restrictive interventions (selective reporting of laboratory susceptibilities, formulary restriction, requiring prior authorization of prescriptions by infectious diseases physicians, microbiologists, pharmacists etc, therapeutic substitutions, automatic stop orders and antibiotic policy change strategies including cycling, rotation and cross-over studies) had a greater effect in the short term in the hospital setting in reducing broad spectrum antibiotics than persuasive interventions (distribution of educational materials; educational meetings; local consensus processes; educational outreach visits; local opinion leaders; reminders provided verbally, on paper or on computer; audit and feedback). However they were both equally effective in controlling antibiotic use and antimicrobial resistance after 6 months. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="55" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The use of audit and feedback processes, which encourage the individual to follow professional standards, have also been found to have an effect on antimicrobial use in the community and care home setting</span><a name="_ftnref28"></a><a href="#_ftn28">[28]</a><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">A study on this issue compared interventions in which audit and feedback was core and evaluated effects on professional practice. The study was able to demonstrate an absolute increase in healthcare professionals’ compliance with desired practice. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="56" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Much work is still required to identify the most effective measures to effect behaviour change in both the public and professionals and this forms a major strand of the UK AMR Strategy. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="57" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AMR is both a national and a global problem, which requires a national and global response led by governments and international organisations such as the EU, WHO and other UN bodies. Progress will only be made if there is a common agenda, and an understanding that the best course of action to tackle AMR can only be brokered if it delivers improvements in a committed, coordinated and efficient way. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Raising the international profile of AMR</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="58" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">With the global nature of AMR in mind, the UK Strategy has an international component which sets out how the Government is actively engaging with the WHO and the EU to press the case for wide ranging action carried out at pace. These activities have taken a variety of forms. An EU roadmap and progress report is expected at the end of 2013.  The Executive Board of the WHO also considered the issue in May 2013 and is expected to produce a progress report. Furthermore, the recently convened a Strategic Technical Advisory group (STAG), which is chaired by the CMO, is designed to help set the direction of future work in this area.  The Government is also working with other Member States to develop a new AMR Resolution for consideration at the next World Health Assembly in May 2014, which will call for the development of a global action plan which focuses on AMR. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="59" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We also believe t</span><span style="font-family:'Times New Roman'; font-size:11pt">he Commonwealth has a potentially key role in helping to galvanise support and drive action in this area, especially with respect to developing infection prevention and control and surveillance capability.  </span><span style="font-family:'Times New Roman'; font-size:11pt">The UK will be spearheading a new</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">initiative which would involve higher income Commonwealth countries “twinning” with lower or middle income Commonwealth countries to improve the capability to monitor, manage and contain AMR, including appropriate support to establish effective hygiene and infection prevention and control measures and surveillance in low income countries</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">By sponsoring this initiative, the UK, is showing its commitment to helping build international capacity to deal with an important aspect of the</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">growing problem of AMR, demonstrating continued global leadership, and a desire to facilitate international co-operation, with the aim of inspiring other developed Commonwealth countries to do likewise. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="60" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Government is also working through the Global Health Security Action Group (GHSAG) which is an informal international network consisting of Canada, the EU, France, Germany, Italy, Japan, Mexico and the UK, to strengthen collaborative working on issues relating to health preparedness and response to global threats of biological, chemical, radio-nuclear terrorism and pandemic influenza. GHSAG may be well placed to use its core capabilities to contribute co-ordinated action at a global level by promoting information and data sharing and exchange on AMR issues, to support WHO in its work programme.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">The pipeline of new antibiotics and novel treatments</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="61" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Government recognises the need for a perpetual supply of new antibiotic drugs and novel treatments to minimise the risks of AMR over time.  The science is complex, and ensuring a sustainable supply of effective antimicrobials cannot be achieved by one country alone. Meanwhile, the present funding systems do not incentivise antimicrobial development. Bringing forward new antibiotics and novel treatments requires innovative approaches in financing research and development activity, which balances the competing needs of conserving the available supply of antibiotics, with private incentives, to maximise return on investment through volumes. The UK is working with others in a wide range of EU and international fora to explore what more can be done to achieve these objectives. </span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="62" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Department of Health is leading a cross-Government work programme to consider the relative merits of various options to stimulate research and development into new antibiotics and novel therapies that may involve both short-term and long-term investment. This includes options to support the basic discovery end of the development pipeline, and incentives that support market-end stages of drug development, which de-couple reimbursement from sales volume, and providing a mechanism linked to effective stewardship. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="63" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 2pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">These issues are also being considered in a range of international forums including Chatham House and the World Innovation Health Summit forum, as well as in discussions with regulators. Harmonisation of regulatory processes is an issue of vital importance, and discussions are in hand at international level to devise innovative business models which incentivise the development of new drugs. Regulators in both</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">EU and US</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">have recently clarified guidance for clinical studies for products intended for multidrug resistant and rare pathogens. </span></li></ol><p style="margin:0pt 2pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="64" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It is likely that greater progress will be made if collaborative, innovative public-private partnerships are encouraged, such as the Innovative Medicines Initiative (UK interests are represented by the Medical Research Council) and Antibiotic Discovery UK (a network of leading academic researchers, Universities and small and medium enterprises aiming to revitalise research on new antibiotics in the UK). The need for cross-research council antibiotic research programmes to supplement the work of existing research councils and charitable bodies has also been raised.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What are the strengths and weaknesses of the Government’s 2013-2018 Strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></p><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="65" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Government recognises that the responsible use of antibiotics in farming is necessary to be able to treat bacterial disease in animals effectively, and to protect animal welfare.</span><span style="font-family:'Times New Roman'; font-size:11pt"> While the scientific consensus is that human prescribing is the main driver for the infections causing serious clinical human infections, responsible prescribing is needed in all sectors. This is why the strategy takes a coordinated “one health” approach </span><span style="font-family:'Times New Roman'; font-size:11pt">to promote consistent messages which will support appropriate prescribing and ensure that </span><span style="font-family:'Times New Roman'; font-size:11pt">antibiotics are used responsibly and only when needed.  </span><span style="font-family:'Times New Roman'; font-size:11pt">To this end, Defra will be reviewing its guidance next year to the farming community to make clear that routine prophylactic use of antibiotics in animals is not acceptable. In addition, further work will be needed to improve our knowledge and understanding of transmission pathways including the potential for antimicrobial resistance strains to be transferred between animals, humans and the wider environment.</span></li></ol><p style="margin:0pt 0pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="66" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In developing the UK Strategy, consideration was given to what measures would have the greatest impact in terms of addressing AMR. The need for approaches which were practical, proportionate and would not duplicate the regulatory framework already in place, were recognised. It was noted that existing European legislation sets out the statutory framework </span><span style="font-family:'Times New Roman'; font-size:11pt">for controls on veterinary medicines, including antibiotics.  Proposals for the revision of this legislation are expected at the end of 2013. The UK, alongside other Member States, are engaging </span><span style="font-family:'Times New Roman'; font-size:11pt">to ensure that future controls placed on the use of veterinary antimicrobials are proportionate and based on scientific evidence.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="67" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 1.9pt 0pt 23.25pt; text-align:justify; text-indent:-23.25pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The new UK AMR Strategy builds on the work of the 2000 strategy, and puts in place a framework to deliver a more integrated and co-ordinated approach, monitoring progress and measuring outcomes more systematically, as well as increase the pace and scale of action needed to have maximum impact. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt 1.9pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="68" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 1.9pt 0pt 23.25pt; text-align:justify; text-indent:-23.25pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The Department of Health is leading delivery of work across Government in the following four areas: AMR research, stimulating the development of new drugs, treatments and diagnostics, improving the evidence base and strengthening international collaboration on AMR.  </span></li><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 1.9pt 0pt 23.25pt; text-align:justify; text-indent:-23.25pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">PHE is leading the management of work related to improving infection prevention and control practices, optimising prescribing practice and improving access to surveillance data, and coordinating work with other relevant organisations and agencies, including, importantly, the NHS and Health Education England. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="70" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 1.9pt 0pt 23.25pt; text-align:justify; text-indent:-23.25pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Defra has overall responsibility for coordinating cross government activity on the animal health aspects of the AMR programme for the UK, which it is doing by co-ordinating work with other relevant organisations. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="71" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 1.9pt 0pt 23.25pt; text-align:justify; text-indent:-23.25pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Implementation of the AMR programme will be overseen by a new High Level Steering Group which will be responsible for developing </span><span style="font-family:'Times New Roman'; font-size:11pt">an appropriate implementation plan and detailed outcome metrics, jointly agreed with delivery partners and expected to be published by April 2014, as well as providing annual progress updates from November 2014 </span><span style="font-family:'Times New Roman'; font-size:11pt">to ensure that the actions being taken enable us to get to a point where:</span></li></ol><p style="margin:0pt 1.9pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 2pt 0pt 33.31pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">good infection prevention and control measures to help prevent infections occurring in the first place become the norm in all sectors of human and animal health;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 2pt 0pt 33.31pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">infections can be diagnosed quickly and the right treatment deployed;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 2pt 0pt 33.31pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">patients and animal keepers fully understand the importance of antibiotic treatment regimens and adhere to them;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 1.9pt 0pt 33.31pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">surveillance is in place which quickly identifies new threats or changing patterns in resistance, and</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 1.9pt 0pt 33.31pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">there is a sustainable supply of new, effective antimicrobials for human use.</span></li></ul><p style="margin:0pt 2pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="72" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt 1.9pt 0pt 23.25pt; text-align:justify; text-indent:-23.25pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The UK Government, led by the Department of Health and the Chief Medical Officer, is also taking an active role in developing the international strategy to address AMR. This includes engaging with a wide range of international bodies, such as G8, WHO, FAO, OIE, the UN and other bodies to create momentum for change and influence the direction of global action to tackle global problems.</span></li></ol><p style="margin:0pt 1.9pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="73" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">While progress is being made, more time is needed for work which has been initiated recently to bed down and mature. Success will inevitably depend on the commitment of partners across all sectors.</span></li></ol><p style="margin:0pt 1.9pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="74" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 1.9pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In addition, work is needed to strengthen our ability to:</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 1.9pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">forecast and model development of antibiotic resistance of critically important antibiotics and multi drug resistant microorganisms over time (the drug-bug combinations);</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 1.9pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">develop  parameters and criteria to help clinicians determine which patients to prescribe what antibiotics, when and over what duration (including the drug/dose aspects); </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 1.9pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">develop alternative and novel approaches to treatment, prioritise treatment options including evaluation of effectiveness of alternatives for particular conditions or circumstances;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 1.9pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">galvanise international collaboration to prevent the global spread of AMR, and</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 1.9pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">engage more effectively with society on the issue, use of behavioural science, and communication mechanisms for take action which will effect positive change. </span></li></ul></ul><p style="margin:0pt 2pt 0pt 23.25pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="75" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 2pt 0pt 18.75pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">challenge of antimicrobial resistance is of such magnitude that, inevitably, no single national strategy can address all the areas of action needed to tackle this global issue. However, the UK Five-Year AMR Strategy 2013-2018 sets the foundation and provides a coordinated </span><span style="font-family:'Times New Roman'; font-size:11pt">basis for further international discussions to develop a common global action plan, and deliver a </span><span style="font-family:'Times New Roman'; font-size:11pt">comprehensive response to the global public health threat posed by AMR.</span></li></ol><p style="margin:0pt 2pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt 2pt 10pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">http://www.who.int/mediacentre/factsheets/fs194/en/</span></p><p style="margin:0pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Calibri; font-size:10pt">h</span><span style="font-family:Calibri; font-size:10pt">ttp://webarchive.nationalarchives.gov.uk/20130107105354/http:/www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4078448.pdf</span></p><p style="margin:0pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">http://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf</span></p><p style="margin:0pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">https://www.gov.uk/government/publications/chief-medical-officer-annual-report-volume-2</span></p><p style="margin:0pt"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">Gram-negative bacteria</span><span style="font-family:Calibri; font-size:10pt"> are </span><a href="http://en.wikipedia.org/wiki/Bacteria"><span style="font-family:Calibri; font-size:10pt">bacteria</span></a><span style="font-family:Calibri; font-size:10pt"> that retain </span><a href="http://en.wikipedia.org/wiki/Crystal_violet"><span style="font-family:Calibri; font-size:10pt">crystal violet</span></a><span style="font-family:Calibri; font-size:10pt"> dye in the </span><a href="http://en.wikipedia.org/wiki/Gram_staining"><span style="font-family:Calibri; font-size:10pt">Gram staining</span></a><span style="font-family:Calibri; font-size:10pt"> protocol, and are associated with resistance against antibiotics.</span></p><p style="margin:0pt"><a name="_ftn6"></a><a href="#_ftnref6">[6]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">https://www.gov.uk/government/publications/uk-5-year-antimicrobial-resistance-strategy-2013-to-2018</span></p><p style="margin:0pt"><a name="_ftn7"></a><a href="#_ftnref7">[7]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">http://www.hpa.org.uk/Publications/InfectiousDiseases/Tuberculosis/1308TBintheUK2013report/</span></p><p style="margin:0pt"><a name="_ftn8"></a><a href="#_ftnref8">[8]</a><span style="font-family:Calibri; font-size:10pt"> Gonorrhoea is a sexually acquired infection caused by the bacterium </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Neisseria gonorrhoeae</span><span style="font-family:Calibri; font-size:10pt">.</span></p><p style="margin:0pt"><a name="_ftn9"></a><a href="#_ftnref9">[9]</a><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:10pt">Data drawn from the following sources:</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">·</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt"> Past and current population estimates for England: </span><a href="http://nww.indicators.ic.nhs.uk/webview/"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://nww.indicators.ic.nhs.uk/webview/</span></a><span style="font-family:Calibri; font-size:10pt">; </span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">·</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt"> ONS population projections from HSCIC population statistics database: </span></p><p style="margin:0pt 0pt 0pt 36pt"><a href="https://login.hscic.gov.uk/Login.aspx?version=4&amp;referrer=http%3a%2f%2fmy.hscic.gov.uk%2f&amp;info=http%3a%2f%2fmy.hscic.gov.uk%3a80%2fSignIn.htm"><span style="font-family:Calibri; font-size:10pt; text-decoration:underline">https://login.hscic.gov.uk/Login.aspx?version=4&amp;referrer=http%3a%2f%2fmy.hscic.gov.uk%2f&amp;info=http%3a%2f%2fmy.hscic.gov.uk%3a80%2fSignIn.htm</span></a></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">·</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt"> PHE Mandatory Surveillance Database of Healthcare Associated Infections.</span></p><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:Calibri; font-size:10pt">DH query on the period January 2011 to September 2013.</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt"> </span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">·</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt"> Residential Care:</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt"> </span><a href="http://www.lse.ac.uk/LSEHealthAndSocialCare/pdf/Dilnot_report.pdf"><span style="font-family:Calibri; font-size:10pt; text-decoration:underline">http://www.lse.ac.uk/LSEHealthAndSocialCare/pdf/Dilnot_report.pdf</span></a><span style="font-family:Calibri; font-size:10pt">; </span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><a name="_ftn10"></a><a href="#_ftnref10">[10]</a><span style="font-family:Calibri; font-size:10pt"> </span><a href="http://www.nice.org.uk/media/842/61/HCAIQualityImprovementGuide.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://www.nice.org.uk/media/842/61/HCAIQualityImprovementGuide.pdf</span></a></p><p style="margin:0pt"><a name="_ftn11"></a><a href="#_ftnref11">[11]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">http://www.nice.org.uk/nicemedia/live/13683/58591/58591.pdf</span></p><p style="margin:0pt"><a name="_ftn12"></a><a href="#_ftnref12">[12]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">http://apps.who.int/iris/bitstream/10665/77376/1/9789241504485_eng.pdf</span></p><p style="margin:0pt"><a name="_ftn13"></a><a href="#_ftnref13">[13]</a><span style="font-family:Calibri; font-size:10pt"> More information on ESPAUR is available at </span><span style="font-family:Calibri; font-size:10pt">http://www.ncbi.nlm.nih.gov/pubmed/24027247</span></p><p style="margin:0pt"><a name="_ftn14"></a><a href="#_ftnref14">[14]</a><span style="font-family:Calibri; font-size:10pt"> These were set out at annex C of the UK Five Year Antimicrobial Resistance Strategy (2013).</span></p><p style="margin:0pt"><a name="_ftn15"></a><a href="#_ftnref15">[15]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">2012-2017</span></p><p style="margin:0pt"><a name="_ftn16"></a><a href="#_ftnref16">[16]</a><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:10pt">These figures do not include investment in wider underpinning research which is important for increasing knowledge of the basic biology of the organisms or hosts. However the EPSRC data does include investment in developing epidemiological models of infectious diseases, techniques to diagnose and monitor infectious disease and novel antimicrobial therapeutics/agents in response to drug resistance.</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><a name="_ftn17"></a><a href="#_ftnref17">[17]</a><span style="font-family:Calibri; font-size:10pt"> See Pharmatimes, September 2013</span></p><p style="margin:0pt"><a name="_ftn18"></a><a href="#_ftnref18">[18]</a><span style="font-family:Calibri; font-size:10pt"> UK Five Year Antimicrobial Resistance Strategy; page 16 -20 (2013).</span></p><p style="margin:0pt"><a name="_ftn19"></a><a href="#_ftnref19">[19]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">http://jac.oxfordjournals.org/content/66/suppl_2/ii41.full</span></p><p style="margin:0pt"><a name="_ftn20"></a><a href="#_ftnref20">[20]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">https://www.gov.uk/government/publications/the-health-and-social-care-act-2008-code-of-practice-on-the-prevention-and-control-of-infections-and-related-guidance</span><span style="font-family:Calibri; font-size:10pt">.</span></p><p style="margin:0pt"><a name="_ftn21"></a><a href="#_ftnref21">[21]</a><span style="font-family:Calibri; font-size:11pt"> </span><a href="http://www.his.org.uk/files/3813/7088/0820/4_epic2_National_Evidence-Based_Guidelines_for_Preventing_Healthcare-Associated_Infections_in_NHS_Hospitals_in_England_2007.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:11pt; text-decoration:underline">http://www.his.org.uk/files/3813/7088/0820/4_epic2_National_Evidence-Based_Guidelines_for_Preventing_Healthcare-Associated_Infections_in_NHS_Hospitals_in_England_2007.pdf</span></a></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><a name="_ftn22"></a><a href="#_ftnref22">[22]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus</span></p><p style="margin:0pt"><a name="_ftn23"></a><a href="#_ftnref23">[23]</a><span style="font-family:Calibri; font-size:11pt"> Prevention and control of infection in care homes - an information resource</span></p><p style="margin:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/214929/Care-home-resource-18-February-2013.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/214929/Care-home-resource-18-February-2013.pdf</span></a></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><a name="_ftn24"></a><a href="#_ftnref24">[24]</a><span style="font-family:Calibri; font-size:11pt"> Antimicrobial prescribing and stewardship competences.</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt"> Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infections and Public Health England.</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt"> (September 2013)</span></p><p style="margin:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/253094/ARHAIprescrcompetencies__2_.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/253094/ARHAIprescrcompetencies__2_.pdf</span></a></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><a name="_ftn25"></a><a href="#_ftnref25">[25]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1294740725984</span><span style="font-family:Calibri; font-size:10pt">.</span></p><p style="margin:0pt"><a name="_ftn26"></a><a href="#_ftnref26">[26]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">http://www.ncbi.nlm.nih.gov/pubmed/21317398</span></p><p style="margin:0pt"><a name="_ftn27"></a><a href="#_ftnref27">[27]</a><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:10pt">Interventions to improve antibiotic prescribing practices for hospital inpatients (2013)</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">Peter Davey, Erwin Brown, Esmita Charani, Lynda Fenelon, Ian M Gould, Alison Holmes, Craig R Ramsay, Philip J Wiffen,</span><span style="font-family:Calibri; font-size:10pt">&#xa0;</span><span style="font-family:Calibri; font-size:10pt"> Mark Wilcox.</span></p><p style="margin:0pt"><a href="http://www1.imperial.ac.uk/resources/0FFB1648-10D4-4CBD-9472-CA6247A9655D/daveypetalcochranedatabaseofsystematicreviews2013.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://www1.imperial.ac.uk/resources/0FFB1648-10D4-4CBD-9472-CA6247A9655D/daveypetalcochranedatabaseofsystematicreviews2013.pdf</span></a></p><p style="margin:0pt"><a name="_ftn28"></a><a href="#_ftnref28">[28]</a><span style="font-family:Calibri; font-size:11pt"> .</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt"> Ivers N, Jamtvedt G, Flottorp S, Young JM, et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012, Issue 6. Art. No.: CD000259. DOI: 10.1002/14651858.CD000259.pub3.</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p></body></html>